A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 13, 2020

Primary Completion Date

September 29, 2022

Study Completion Date

September 29, 2022

Conditions
Urinary Bladder Neoplasms
Interventions
DRUG

E7766

E7766, solution, intravesically.

Trial Locations (9)

10029

The Mount Sinai Hospital, New York

32224

Mayo Clinic Jacksonville, Jacksonville

43210

Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

46202

Indiana University, Indianapolis

63110

Washington University, St Louis

85234

Banner MD Anderson Cancer Center, Gilbert

90033

University of Southern California, Los Angeles

90404

UCLA, Santa Monica

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

H3 Biomedicine Inc.

INDUSTRY

lead

Eisai Inc.

INDUSTRY